EDN1 and metabolic dysfunction-associated steatohepatitis: ET‐1 is increased in NASH patients, serum levels correlate with the severity of fibrosis, and blocking ET‐1 decreases fibrosis making it of interest when investigating therapeutic concepts for NASH.12